Genzyme announces positive interim results of its MS drug

Genzyme has announced that its drug Lemtrada (alemtuzumab) for multiple sclerosis has shown positive interim results


No new safety signals were identified in the study

Genzyme's multiple sclerosis drug, Lemtrada (alemtuzumab) has shown positive interim results in the second year of its extension study.

In these studies, Lemtrada was given as two annual courses, one at the start of the study and other 12 months later. The study found that, relapse rates and sustained accumulation of disability remained low among patients who had previously received the drug in any of the Phase III CARE-MS I and CARE-MS II studies. No new safety signals were identified.

"These extension study results provide further evidence of the prolonged efficacy of Lemtrada on both relapses and disability. The majority of patients continued to experience reduced disease activity, even though their last Lemtrada treatment was three years earlier," said Dr Alasdair Coles, senior lecturer, Department of Clinical Neurosciences, University of Cambridge.

More than 90 percent of the patients who were treated with Lemtrada in the Phase III trials enrolled in the extension study.

The results of the study will be presented at the European Committee for Research and Treatment in Multiple Sclerosis meeting in Boston.


1 Comment Comment 1 - 1 of 1

Sondra dickinson 15 January 2015 at 06:36 AM

On Tysabri , 3rd ms medicine. Very interested in Lemtrada, dr gettin approved and financial grants/assistance


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email